- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Oliver McFarlane syndrome and choroidal neovascularisation: a case report. (Pubmed Central) - Jun 22, 2021 To prevent potential systemic complications during anti-VEGF administration, the systemic status of patients with ARMD should be evaluated before the injection and those with a risk of high SABP during injection should be closely monitored. We report the first case of CNV secondary to OMS and its successful treatment with intravitreal anti-vascular endothelial growth factor injections.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical: Comparison of Two Different Intravitreal Injection Techniques. (Pubmed Central) - Jun 22, 2021 P=N/A The IIG appears to significantly reduce procedure time, be associated with a lower incidence of subconjunctival hemorrhage and engender better patient acceptance. ClinicalTrials.gov (NCT04455399).
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: RainbowExt: Rainbow Extension Study (clinicaltrials.gov) - Jun 15, 2021 P3, N=180, Active, not recruiting, Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully. Trial completion date: Oct 2022 --> May 2022 | Trial primary completion date: Oct 2022 --> May 2022
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Journal: Secondary choroidal neovascularization due to choroidal osteoma after 9 years follow-up. (Pubmed Central) - Jun 8, 2021 Optical coherence tomography angiography combined with FFA and ICGA is used to analysis the characteristics of secondary choroidal neovascularization. Optical coherence tomography angiography can reveal some unique characteristics in the vascular changes compared to fundus fluorescein angiography.
- |||||||||| CMAB818 (ranibizumab biosimilar) / 3SBio
Enrollment open: Phase I Study to Compare CMAB818 Injection and Lucentis (clinicaltrials.gov) - Jun 8, 2021 P1, N=24, Recruiting, Optical coherence tomography angiography can reveal some unique characteristics in the vascular changes compared to fundus fluorescein angiography. Not yet recruiting --> Recruiting
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. (Pubmed Central) - Jun 5, 2021 To assess the development of macular atrophy, according to the new Classification of Atrophy Meetings criteria, in patients with treatment-naïve neovascular age-related macular degeneration during the first year of treatment with ranibizumab or aflibercept, and to determine baseline factors predictive of atrophy development...Predictors of atrophy development have the potential to change treatment practices. Further research is warranted.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Retrospective data, Review, Journal: Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis. (Pubmed Central) - May 28, 2021 One year after ranibizumab treatment, the area and perimeter of the FAZ were enlarged, while the VD of the SCP and DCP remained stable, which indicated that ranibizumab treatment did not improve macular blood supply and macular ischemia in BRVO patients. Intravitreal conbercept was associated with a more significant BCVA improvement, better intraoperative outcome, and less postoperative vitreous hemorrhage compared to no conbercept.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Current intravitreal therapy and ocular hypertension: A review. (Pubmed Central) - May 28, 2021 The studies that reported on short-term IOP elevation (i.e., between 0 and 60 min) showed that an immediate increase in IOP is seen in all patients who receive anti-VEGF agents or triamcinolone acetonide when measured between 0 and 30 min of intravitreal injection and that the IOP elevation decreases over time...Most, if not all, intravitreal agents cause ocular hypertension, both in the short term and long term. The functional consequences of these observations are not very clear.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. (Pubmed Central) - May 28, 2021 In addition, the FGF receptor tyrosine kinase inhibitor BGJ398, the pan-FGF trap NSC12, the heparin-binding protein antagonist N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe Boc2, and the anti-inflammatory hydrocortisone all inhibited Müller cell activation mediated by PDR vitreous. These findings point to a role for various modulators beside VEGF in Müller cell activation and pave the way to the search for novel therapeutic strategies in PDR.
|